纳武利尤单抗治疗期间甲状腺功能检测的免疫分析干扰
一例85岁转移性黑色素瘤患者接受纳武利尤单抗后出现严重免疫检查点抑制剂相关甲状腺毒症,在Siemens Centaur免疫分析中游离甲状腺素(fT4)水平不适当升高且未如预期下降,换用Roche Elecsys及聚乙二醇6000沉淀后均证实fT4适当降低,提示纳武利尤单抗可能诱导生化干扰;停药后干扰消失。
要点
- PD-1/PD-L1抑制剂与甲状腺功能障碍发生率升高相关。
- 纳武利尤单抗治疗期间可能出现fT4免疫分析生化干扰,导致结果假性升高。
- 更换免疫分析方法或聚乙二醇6000沉淀可协助识别该干扰。
核心结论
- 作者报告一例可能的纳武利尤单抗诱导的fT4检测生化干扰,停药后干扰消失支持药物诱导干扰的假设。
- 作者指出需进一步研究证实该干扰的生化机制。
研究设计与样本
- 病例报告:一例85岁转移性黑色素瘤患者接受纳武利尤单抗治疗。
- 基线抗癌治疗前甲状腺功能检测正常。
主要发现
- 第二次纳武利尤单抗给药后数日出现严重甲状腺毒症。
- 按破坏性甲状腺炎病程,促甲状腺激素(TSH)短期正常化并快速升高,但fT4不适当升高且未如预期下降。
- 同一标本换用Roche Elecsys免疫分析复测证实严重甲状腺功能减退伴fT4适当降低。
- 同一标本经聚乙二醇6000沉淀后用Siemens Centaur免疫分析检测显示fT4适当降低。
- 开始左甲状腺素(LT4)治疗并每月用Roche免疫分析监测甲状腺功能;约9个月后建议停用纳武利尤单抗,1个月后Siemens Centaur复测显示在充分LT4替代治疗下fT4水平适当且TSH正常。
局限性
- 作者指出需进一步研究证实该干扰的生化机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Immune checkpoint inhibitors (ICIs) are associated with several endocrine side effects. In particular, the use of programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors is related to a higher incidence of thyroid dysfunction. Patient Findings: An 85 years-old patient, diagnosed with a metastatic melanoma treated with nivolumab, presented to our hospital with severe ICI-related thyrotoxicosis. Diagnosis was complicated by a biochemical interference on thyroid hormones assay, probably induced by nivolumab. Summary: Baseline laboratory examination conducted before onset of anticancer therapy showed normal thyroid function test (TFTs). A few days after receiving the second nivolumab administration, the patient developed a severe thyrotoxicosis. According to destructive thyroiditis, in a short period thyrotropin (TSH) levels normalized and rapidly increased, but free thyroxine (fT4) levels were inappropriately elevated and did not decrease as expected. The sample was processed by using a Siemens Centaur® immunoassay. We reanalyzed the same sample at another laboratory and with a different immunoassay method (Roche Elecsys®). The results obtained from this assay confirmed severe hypothyroidism with appropriately low fT4 levels. We suspected a possible nivolumab-associated interference on the fT4 assay. Therefore, we subjected the same sample to a polyethylene glycol (PEG) 6000 precipitation, a simple method for the removal of macromolecules, before assaying for fT4 levels. Evaluation of the post-PEG-precipitation sample (Siemens Centaur immunoassay) revealed appropriately low fT4 levels. The patient was started on levothyroxine (LT4) therapy, with monthly TFT monitoring using the Roche immunoassay. Approximately 9 months after starting nivolumab therapy, the patient was advised treatment cessation. A month later, the TFTs were retested on a Siemens Centaur immunoassay, and appropriate fT4 levels were observed in accordance with normal TSH levels on adequate LT4 replacement therapy. Conclusions: We report a possible novel nivolumab-induced biochemical interference on assays of fT4 levels. The hypothesis of a biochemical drug-induced interference is further supported by the disappearance of the interference after the withdrawal of nivolumab. Further studies are needed to prove the biochemical mechanisms of this interference.
引用
- Paragliola RM, Corsello A, Papi G, et al. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab. Thyroid. 2020. PMID: 32122271. doi:10.1089/thy.2019.0799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。